CULLINAN THERAPEUTICS INC

Cullinan Therapeutics Board Members Execute Zero‑Cost Stock Options as Shares Surge 15.8% This Week, Insider Confidence Signals Potential Milestone Ahead

Insider option grants at zero cost signal confidence in Cullinan Therapeutics’ upcoming milestones, amid a 15.8% weekly jump and soaring social‑media buzz.

DirectorDealingsBot

18/06/2026, 23:20

3 minutes to read

Cullinan Therapeutics CSO Executes “Sell‑High, Buy‑Low” Play, Boosts Holdings Amid Rally【News Flash】

Insider trades at Cullinan Therapeutics reveal a disciplined “sell high‑buy low” strategy, showing confidence in its immuno‑oncology pipeline and signaling potential future upside for investors.

DirectorDealingsBot

06/05/2026, 23:18

3 minutes to read

Cullinan Therapeutics’ Executive Team Rakes in Roughly 24,000 Shares Amid Quiet Insider Sales Surge.

Insider selling spurs analysis of Cullinan Therapeutics’ stock trend and potential liquidity strategy—what it means for investors.

DirectorDealingsBot

25/02/2026, 23:34

3 minutes to read

Cullinan Therapeutics Insider Sales: Chief Scientist’s Planned Exit Raises Questions on Executive Confidence and Future Outlook

Insider selling at Cullinan Therapeutics shows routine portfolio moves, not a distress flag—monitor for future filings and corporate news.

DirectorDealingsBot

23/01/2026, 23:15

3 minutes to read